Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023421 | 0.85 | FPR2 (0.54) | GPR119FPR2FNTAFNTB | |
| SCHEMBL2023076 | 0.85 | GPR119 (0.48) | GPR119FPR2 | |
| SCHEMBL17796167 | 0.85 | GPR119 (0.46) | GPR119ALKFPR2DRD2NOTCH1 | |
| SCHEMBL5240763 | 0.85 | GRM5 (0.48) | — | |
| SCHEMBL2023761 | 0.84 | BACE1 (0.51) | GPR119 | |
| SCHEMBL6152303 | 0.83 | HTR1A (0.53) | GPR119FPR2 | |
| SCHEMBL5250180 | 0.80 | ESR2 (0.50) | GPR119FPR2 | |
| SCHEMBL835761 | 0.80 | GPR119 (0.47) | GPR119FPR2 | |
| SCHEMBL17796204 | 0.77 | FNTA (0.42) | GPR119FNTAFNTB | |
| SCHEMBL22374272 | 0.77 | PIK3CA (0.44) | GPR119ALKDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GPR119 24/4885ALK 3801/4885FPR2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.